Guardant Health (GH) Statistics

Guardant Health Inc (GH) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. From early cancer detection to treatment monitoring and assessing minimal residual disease, Guardant Health offers a comprehensive suite of solutions for cancer patients. Founded in 2012, the company has rapidly established itself as a pioneer in the liquid biopsy space, revolutionizing the way cancer is detected and monitored. Guardant Health's mission is to transform cancer care by enabling precision oncology across all stages of the disease.

When it comes to GH's stock statistics, it is important to note that as of the date of this writing, the stock is traded on the NASDAQ under the ticker symbol GH. GH's current valuation metrics indicate a promising outlook for investors. With a market capitalization of over $10 billion, GH has a substantial presence in the precision oncology market. The stock's fundamentals are also strong, with positive revenue growth and a healthy profit margin. Additionally, GH has a relatively low amount of total debt, which is favorable for long-term investors.